5468-71-3 Usage
General Description
3,5-dichloropicolinamide is a chemical compound with the molecular formula C6H3Cl2N2O. It is a derivative of picolinic acid and belongs to the class of pyridine compounds. This chemical is used as a herbicide and is commonly applied to control broadleaf weeds and grasses in various agricultural crops. It works by inhibiting the enzyme protoporhyrinogen oxidase, leading to the accumulation of reactive oxygen species and ultimately causing cell death in the targeted plants. 3,5-dichloropicolinamide is considered to have a low acute toxicity to mammals and is relatively stable in the environment, but it may pose a risk to aquatic organisms and other non-target species. Despite its effectiveness in weed control, proper precautions should be taken when handling and applying this chemical to minimize its impact on the environment and human health.
Check Digit Verification of cas no
The CAS Registry Mumber 5468-71-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,4,6 and 8 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 5468-71:
(6*5)+(5*4)+(4*6)+(3*8)+(2*7)+(1*1)=113
113 % 10 = 3
So 5468-71-3 is a valid CAS Registry Number.
InChI:InChI=1/C6H4Cl2N2O/c7-3-1-4(8)5(6(9)11)10-2-3/h1-2H,(H2,9,11)
5468-71-3Relevant articles and documents
PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE
-
Page/Page column 152; 153; 155, (2014/09/29)
PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE ABSTRACT OF THE DISCLOSURE The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: {INSERT STRUCTURE HERE} I wherein variables A4, A5, A6, A8, each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.
